LHRH Agonists Articles

Androgen deprivation therapy (ADT) is the standard treatment for metastatic prostate cancer. It has increasingly been used in other stages of the disease as well. Besides well-known side effects caused by the lack of testosterone (impotency, osteoporosis, fatigue, loss of muscle mass), an increase of cardiovascular (CV) morbidity and mortality has recently been discussed in association with ADT.

Truckee, CA (UroToday.com) - Degarelix is the most widely available and extensively studied gonadotrophin-releasing hormone (GnRH) antagonist for the treatment of advanced prostate cancer (PCa).  Degarelix displays a different pharmacological profile to luteinizing hormone-releasing hormone (LHRH) agonists which suggests several potential clinical advantages.

BERKELEY, CA (UroToday.com) - This article is one of a series of studies that my colleagues and I have published in the last year related to helping prostate cancer (PCa) patients recognize and adapt to the side effects of androgen deprivation therapy (ADT).